MCRB

$4.48-$0.24 (-5.08%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$47.4M

10M shares

52-week range

$4.46 – $29.98

0% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-126.32

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$14M	+5073.9%	$-3.52	$-3.52–$-3.52	—	1
2027	$273500	-98.0%	$-4.95	$-4.95–$-4.95	—	1
2028	$273500	+0.0%	$-4.97	$-4.97–$-4.97	—	1
2029	$547000	+100.0%	$-8.64	$-8.64–$-8.64	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-05	$-2.18	$0.47	+121.6%
2026-05-05	$-1.88	$-2.08	-10.6%
2026-03-12	$-2.39	$-1.89	+20.9%
2025-11-05	$0.05	$0.94	+1780.0%
2025-08-06	$-2.72	$-2.27	+16.5%
2025-05-07	$-0.67	$-2.24	-234.3%
2025-03-13	$-0.17	$-0.32	-88.2%
2024-11-13	$-5.00

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
MCRBSeres Therapeutics, Inc.	$4.48	-5.08%	$43M	—
ABOSAcumen Pharmaceuticals, Inc.	$2.55	+1.59%	$184M	—
ACTUActuate Therapeutics Inc	$0.98	-0.48%	$23M	—
APLTApplied Therapeutics, Inc.	$0.10	+0.00%	$15M	—
CGTXCognition Therapeutics, Inc.	$1.04	+0.00%

Seres Therapeutics, Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

www.serestherapeutics.com

Employees: 66
IPO / List date: Jun 26, 2015
HQ: CAMBRIDGE, MA

Held by traders on TradeandTell

No one on the platform currently holds MCRB.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in MCRB as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2025-04-22	1-for-20reverse

Recent trades on TradeandTell

No one on the platform has traded MCRB yet.

$MCRB chatter on StockTwits

Getting Big NP@GettingBigNPBullish1h
$MCRB $XBI $IBB This is exactly how I’m looking at it. The current valuation makes very little sense to me relative to the platform potential. Allo-HSCT + irEC gives them multiple shots on goal. Accumulating at these all-time lows and waiting is the easy part. The hard part will be what to do if this thing goes on a crazy run. Last year, if you didn’t sell some in the 10s, 20s, or 30s you left a fortune on the table. The dream scenario is waking up to a buyout and not having to make any decisions at all. 😂 If negotiations are developing, letting the stock drift on low volume while things get lined up would make plenty of sense. I’m not saying an acquisition is guaranteed, but the setup is certainly consistent with one. At these levels, I’m happy to keep accumulating.
View on StockTwits ↗
Erol@Magnificient6h
$MCRB volume yesterday was Average Volume 99,984 is tht right?
View on StockTwits ↗
Tritsortreat2020@Tritsortreat202014h
$MCRB ill throw another 50k if we see a FUD day tomorrow morning. our time will come
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish14h
$MCRB $XBI $IBB S-3 just dropped and I’m sure the FUD crew will be quick to scream “dilution/ATM incoming.” Reality: the prior S-3 was filed Aug. 8, 2023 and had a 3-year term, so it was expiring right around now. Today’s filing looks like a straightforward shelf replacement to preserve financing flexibility. An S-3 ≠ an offering. An ATM ≠ shares being sold.
View on StockTwits ↗
Sam@BigBull00514h
$MCRB
View on StockTwits ↗
Ashok Sekar@Bullbullthara15h
$MCRB @RoelInTheGreen Move on dude, you are not helping anyone here ... if you have anything valuable to share here, which we don't know already... otherwise move on ...looks like you can't get over with it ....
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish16h
$MCRB $XBI $IBB @RoelInTheGreen You say the company is worth way more than the current market cap, but the past has kept you from buying. Fair enough. So what price would actually make you pull the trigger? Are you buying yet at these levels, or is there a specific price where the risk/reward becomes too compelling to ignore?
View on StockTwits ↗
Roel@RoelInTheGreenBearish16h
$MCRB you should ask yourself why there is only 6K volume.
View on StockTwits ↗
panter@panterms17h
$MCRB wow 👌 👌.. MCRB 4.50 share price is lowest in company history. Losers scums making money now .
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish19h
@SBGood Yep, we do… **until we don’t.** 😂 That’s the game. But honestly, I can’t remember a better spot to enter $MCRB than right now. The risk/reward here looks extremely compelling while we wait for a partnership/asset sale/acquisition..
View on StockTwits ↗
Cheesyisi@Cheesyisi19h
$MCRB added 1k shs @ 4.53
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish19h
$MCRB $XBI $IBB coiled up like a serpent waiting to strike 🐍 Bullish divergence showing up across the **4H, 1D, 1W AND 1M** timeframes. Feels like the fuse is lit… just waiting for the **BOOM.** C’mon management, get that deal across the finish line and let the PR fly. 💥📈
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish20h
$MCRB $XBI $IBB Down 5% on a grand total of 6k daily volume
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish21h
@ACInvestorBlog Always love to see the highly respected Mr. Costa in any of my current positions! We could use you back in $MCRB my friend. Phenomenal entry here at literal all time lows, check my posts to see why I’m so bullish on it. The setup looks great and if you are into technicals it has bullish divergence on every higher timeframe as well.
View on StockTwits ↗
Getting Big NP@GettingBigNPBullish21h
$MCRB $XBI $IBB Personally, I think the risk/reward is extremely compelling at a sub ~$50M market cap. ✅ No debt ✅ Cash runway into 2027 ✅ Breakthrough Therapy + Fast Track designations ✅ Strong SER-155 data ✅ Expansion into irEC, with management engaging potential partners, including companies with ICI franchises ✅ Management is considering sources of financing while evaluating the next steps for SER-155, suggesting they have multiple paths available to advance the program ✅ Directors chose stock options instead of annual cash compensation, further aligning themselves with shareholders I continue to believe a partnership or potentially even an acquisition is a very real possibility over the coming months. Patiently waiting 💰
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.